Metrosa

Metronidazole, the active ingredient in Metrosa, is a nitroimidazole presented as a topical formulation for skin use. It is used to manage inflammatory skin conditions such as rosacea in adults. GNH USA supplies Metrosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metronidazole is indicated for the treatment of inflammatory skin disorders, particularly those involving anaerobic bacterial overgrowth.

- Rosacea: reduces papules, pustules and erythema associated with facial rosacea.

Metrosa may cause a range of skin‑related adverse reactions.

Common Side Effects: - Skin irritation: mild redness or discomfort at the application site - Dryness: localized dryness or flaking of the skin - Burning sensation: transient warmth or stinging after application - Itching: pruritus localized to treated area - Peeling: superficial desquamation of the epidermis - Hyperpigmentation: temporary darkening of the skin

Serious or Rare Side Effects: - Allergic reaction: hives, swelling, or difficulty breathing - Severe dermatitis: extensive rash or blistering - Photosensitivity: heightened skin sensitivity to sunlight - Contact dermatitis: persistent inflammation at the site - Systemic effects: rare nausea or headache if absorbed in large amounts - Anaphylaxis: life‑threatening allergic response requiring emergency care

When using Metrosa, consider the following safety measures.

- Allergy assessment: confirm no known hypersensitivity to metronidazole or nitroimidazoles - Application area: avoid use on broken, ulcerated, or severely inflamed skin - Duration of therapy: limit use to the period prescribed by a healthcare professional - Concomitant products: avoid simultaneous use of other topical irritants unless directed - Monitoring: watch for signs of allergic reaction or worsening skin condition - Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight

Metrosa may interact with other substances; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Alcohol consumption: risk of disulfiram‑like reaction causing flushing and nausea - Systemic metronidazole: concurrent systemic therapy may increase systemic exposure

Moderate Interactions (Monitor Closely): - Other topical antibiotics: potential additive irritation - Topical corticosteroids: may alter absorption or efficacy - Warfarin: theoretical increase in anticoagulant effect if systemic absorption occurs - Anticonvulsants: possible interaction with hepatic enzymes